On Friday, in the course of current trade, Shares of Koninklijke Philips NV (ADR) (NYSE:PHG), dropped -2.04%, and is now trading at $ 27.42.
Koninklijke Philips, declared the introduction of HeartModelA.I., a new Anatomically Intelligent Ultrasound (AIUS) tool that brings advanced quantification, automated 3D views and robust reproducibility to cardiac ultrasound imaging. Philips’ fastest 3D AIUS ultrasound measurement method was unveiled on its EPIQ 7 ultrasound system, Philips’ first ultrasound with Anatomic Intelligence capabilities, during the American Society of Echocardiography (ASE) annual meeting in Boston, Mass.
Koninklijke Philips N.V. engages in healthcare, consumer lifestyle, and lighting businesses worldwide. It provides various integrated clinical solutions, counting radiation oncology and portfolio administration; computed tomography, magnetic resonance imaging, and molecular imaging products; digital X-ray and mammography products; interventional X-ray products in cardiology, radiology, surgery, and other areas; and ultrasound products.
During an Afternoon trade, Shares of Analog Devices, Inc. (NASDAQ:ADI), dipped - 1.54%, and is now trading at $ 66.18.
Analog Devices, Inc. introduced a highly integrated, 4-channel, 24-GHz receiver down-converter MMIC with the industry’s best combination of low-noise performance, high linearity and low-power consumption. The ADF5904 integrated, multi-channel receiver down-converter achieves a 10-dB noise figure that is 3 dB better than competing devices, while using 50 percent less power, and is assembled in a small, cost-effective 5 × 5 mm LFCSP plastic package. Each of the device’s four on-chip receive channels use a simple, single-ended connection to four individual antennas, which simplifies RF-transmission-line design and PCB layout, and reduces board size. The receiver down-converter then simultaneously handles four receive signals directly to produce a high-quality, high-amplitude baseband signal that easily connects to one of ADI’s four-channel analog-to-digital converters. The ADF5904 also incorporates an integrated temperature sensor that eliminates the need for discrete sensing components that otherwise can require additional time and resources to calibrate during system assembly and test.
Analog Devices, Inc. engages in the design, manufacture, and marketing of analog, mixed-signal, and digital signal processing integrated circuits (ICs) for use in industrial, automotive, consumer, and communication markets worldwide.
Finally, Merge Healthcare Inc. (NASDAQ:MRGE), gained 0.35% Friday, hitting its highest level.
Study Connect(TM), a new mobile app from Merge eClinical, allows eClinicalOS (eCOS) users to perform a wide array of clinical trial administration functions from their iOS-based mobile devices.
Seamlessly integrated with eCOS, Study Connect(TM) enables researchers to:
- Manage randomization of subjects
- Coordinate dispensing and inventory administration
- Unblind individual subjects, as circumstances warrant
- Stay connected with real-time customized notifications
- Monitor enrollment and establish milestone alerts
- Share top-level statistics for each study with key stakeholders using the study dashboard
- Expedite approval response times for critical study decisions such as patient study eligibility
- Maintain security with the ability to set customized role-based permissions for individual studies.
Merge Healthcare Incorporated develops software solutions that facilitate the sharing of images to create an electronic healthcare experience for patients and physicians worldwide. It operates in two segments, Merge Healthcare and Merge DNA.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
